Roland Walter, M.D., Ph.D., M.S.
Roland Walter, M.D., Ph.D., M.S.
Associate Member
Clinical Research Division, Fred Hutch
Dr. Roland Walter is a hematologist who specializes in treating acute myeloid leukemia, or AML. His research seeks to develop new and improved antibody-based therapies in the laboratory that effectively kill AML cells, including treatments that eradicate the AML stem cells, and then to bring these therapies to patients.
Other Appointments & Affiliations
Associate Professor of Medicine, Division of Hematology
University of Washington School of Medicine
Adjunct Associate Professor, Department of Epidemiology
University of Washington School of Public Health
Adjunct Associate Professor, Department of Pathology
University of Washington School of Medicine
Education
Medical School, University of Zürich, 1990-96
M.D., Faculty of Medicine, University of Zürich, 1997
Resident, Internal Medicine, Rätisches Kantons- und Regionalspital, Chur, Switzerland, 1997-99
Resident, Internal Medicine, University Hospital, Zürich, Switzerland, 1999-02
Ph.D., University of Washington, 2006
Research Fellow, Clinical Research Division, 2002-08
Fellow, Division of Hematology, University of Washington, 2005-07
M.S., Epidemiology, Clinical Research, University of Washington, 2011
Research Interests
The preclinical and early clinical development and characterization of novel antigen-directed immunotherapies for AML
The conduct of trials testing novel treatments and innovative and innovative care approaches for AML patients
Approaches to develop and improve diagnostic and prognostic tools in AML
Active Clinical Trials
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm
Study Number: 10000
Phase: I/II
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
Study Number: 10049
Phase: I
A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Study Number: 9382
Phase: I
Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Study Number: 9919
Phase: I
A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study
Study Number: 9920
Phase: I/II
SEL24 in Patients With AML
Study Number: 9982
Phase: I/II
Study of APVO436 in Patients With AML or MDS
Study Number: RG1003382
Phase: I
Dr. Walter in the News
For the Media
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email media@fredhutch.org or call 206.667.2210